Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor
- Evaluate the impact of epoetin beta on fatigue and quality of life of patients
receiving palliative care for malignant solid tumors.
- Evaluate the impact of epoetin beta on hemoglobin level (increase > 2 g/dL).
OUTLINE: Patients receive epoetin beta subcutaneously once a week for up to 3 months.
Fatigue, quality of life, and hemoglobin and reticulocyte levels are assessed every 4 weeks.
Allocation: Non-Randomized, Primary Purpose: Supportive Care
Centre Hospital Regional Universitaire de Limoges
United States: Federal Government